Modeling viral dynamics in HIV/AIDS studies has resulted in a deep understanding of pathogenesis of HIV infection from which novel antiviral treatment guidance and strategies have been derived. Viral dynamics models based on nonlinear differential equations have been proposed and well developed over the past few decades. However, it is quite challenging to use experimental or clinical data to estimate the unknown parameters (both constant and time-varying parameters) in complex nonlinear differential equation models. Therefore, investigators usually fix some parameter values, from the literature or by experience, to obtain only parameter estimates of interest from clinical or experimental data. However, when such prior information is not available, it is desirable to determine all the parameter estimates from data. In this paper we intend to combine the newly developed approaches, a multi-stage smoothing-based (MSSB) method and the spline-enhanced nonlinear least squares (SNLS) approach, to estimate all HIV viral dynamic parameters in a nonlinear differential equation model. In particular, to the best of our knowledge, this is the first attempt to propose a comparatively thorough procedure, accounting for both efficiency and accuracy, to rigorously estimate all key kinetic parameters in a nonlinear differential equation model of HIV dynamics from clinical data. These parameters include the proliferation rate and death rate of uninfected HIV-targeted cells, the average number of virions produced by an infected cell, and the infection rate which is related to the antiviral treatment effect and is time-varying. To validate the estimation methods, we verified the identifiability of the HIV viral dynamic model and performed simulation studies.
Proximal Learning for Trials With External Controls: A Case Study in HIV Prevention
Columbia University(哥伦比亚大学);University of Washington(华盛顿大学);David Geffen School of Medicine, University of California, Los Angeles(加州大学洛杉矶分校大卫格芬医学院);Bridge HIV, San Francisco Department of Public Health(旧金山公共卫生局桥接艾滋病项目);Emory University(埃默里大学);National Institute of Allergy and Infectious Diseases(美国国家过敏和传染病研究所);St. Jude Children’s Research Hospital(圣裘德儿童研究医院);University of Michigan(密歇根大学)
Debiasing hazard-based, time-varying vaccine effects using vaccine-irrelevant infections: An observational extension of a pivotal Phase 3 COVID-19 vaccine efficacy trial
University of Washington(华盛顿大学);Fred Hutchinson Cancer Center(弗雷德·哈钦森癌症中心);National Institute of Allergy and Infectious Diseases(美国国家过敏和传染病研究所);Brigham and Womens’ Hospital, Harvard Medical School(布莱姆妇女医院,哈佛医学院);Baylor College of Medicine(贝勒医学院)
Pharmacokinetics Simulations for Studying Correlates of Prevention Efficacy of Passive HIV-1 Antibody Prophylaxis in the Antibody Mediated Prevention (AMP) Study